Twitter | Search | |
Search Refresh
Gil Morgan Oct 13
TONIGHT‼️ As the Virtual Train to 🚂heads back to Europe🇪🇺for Educational📚 WE make a STOP🚏in my home state of TEXAS🇺🇸for A Great Social Media Mentorship Session w/ & myself Warm invite to ALL to participate🤠 Register here
Reply Retweet Like
Brendon Stiles Oct 1
Reply Retweet Like
Laurie Glimcher MD Oct 2
New findings from CheckMate 9ER, a pivotal study presented by during , shows new hope for patients with advanced kidney cancer through immunotherapy combination.
Reply Retweet Like
Jose M Martin-Moreno Oct 16
Excited to be part of this session 3 on cancer prevention today at 16:10 ... 👍 (channel 5)
Reply Retweet Like
soria Sep 22
To all my colleagues & friends, I truly hope to see you physically in for
Reply Retweet Like
Brendon Stiles Oct 1
T5. I thought did a great job. So did
Reply Retweet Like
FabriceAndre Sep 21
InPATential 150 trial shows that targeting AKT in PTEN-loss prostate cancer improves outcome. PTEN mutations were discovered by reseachers from Columbia U in 1997 when I was doing my first year fellowship. The paper made lot of noise at this time
Reply Retweet Like
drcammclaren Sep 25
Poster on my first 50 VAD cases in Victoria, presented at .
Reply Retweet Like
Thoracic Oncology Group of Australasia Sep 28
Join us tonight to hear the lung cancer highlights from virtual meeting, and to introduce . Join us tonight to hear from Nick Pavlakis and Jenny Lee To register :
Reply Retweet Like
VJ Oncology Oct 15
Reply Retweet Like
JQ Sep 21
It’s easier to see why initiated so many Pembrolizumab+Lenvatinib combination ph3 trials in various tumor types and settings - PD1/PD-L1 naive and post PD1/PD-L1 - after seeing more data presentations from . There are some toxicity but range of efficacy impressive.
Reply Retweet Like
Andres Cervantes Sep 26
Amazing numbers for the first virtual 2020 Congress. The educacion Weekend is about to come.
Reply Retweet Like
ESMO - Eur. Oncology Oct 15
Education Weekend starts in few hours 🙌🚀with an extensive programme looking into the latest challenges in . Check out the sessions in today's programme 👇 and see you online for Q&As and live discussions
Reply Retweet Like
Sara Fontanella Chiarani Sep 21
This team really nailed it
Reply Retweet Like
Breastcancer.org 53s
ASCENT trial results show Trodelvy offers better outcomes than standard chemo for previously treated metastatic triple-negative breast cancer
Reply Retweet Like
Vadim Koshkin MD Sep 23
One of key takeaways from in with studies like Danube and Keynote-361 reading out negative is that frontline SOC remains platinum-based chemo now followed by avelumab maintenance
Reply Retweet Like
Shannon Westin Sep 21
There was no difference in PFS or OS among women w/ recurrent treated with nivolumab vs standard chemotherapy (gemcitabine or pegylated liposomal doxorubicin).
Reply Retweet Like
Dr. Iván R. González Sep 24
Association of 😋☕️ With Survival in Patients With Advanced or Metastatic
Reply Retweet Like
#LCSM Chat Oct 1
Chat Topic 10/01/2020: Crazy year, crazy progress– at . Join moderator as we recap this important conference. Read more here:
Reply Retweet Like
Benjamin Besse Sep 20
THANK YOU my dear colleague Cécile Le Pechoux: you bravely answered a very frequent tumor board question: in 2020, adjuvant RT is not standard of care in resected N2 NSCLC. Some said PACIFIC was THE SoC in stage III-N2 NSCLC but look at OS, surgery is not dead!
Reply Retweet Like

Related searches

@myesmo · @oncoalert